Arthroscopy News and Research

RSS

Arthroscopy (also called arthroscopic surgery) is a minimally invasive surgical procedure in which an examination and sometimes treatment of damage of the interior of a joint is performed using an arthroscope, a type of endoscope that is inserted into the joint through a small incision. Arthroscopic procedures can be performed either to evaluate or to treat many orthopaedic conditions including torn floating cartilage, torn surface cartilage, ACL reconstruction, and trimming damaged cartilage.

FDA grants Thermedx 510(k) clearance for optional fluid warming in arthroscopic, hysteroscopic procedures

Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.

30 Jun 2014

Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today announced that the United States Patent and Trademark Office has issued five new patents directed to the Subchondroplasty® Procedure, the innovative new joint preservation procedure developed by Zimmer Knee Creations: U.S. Patent No. 8,551,178, U.S. Patent No. 8,574,303, U.S. Patent No. 8,608,802, U.S. Patent No. 8,617,166 and U.S. Patent No. 8,623,089.

25 Feb 2014

eInfochips launches Andromeda Reference Platform for medical imaging and telemedicine designers

The video processing system includes the system hardware and software that design teams need for fast time-to-application development

5 Feb 2014

Viewpoints: Target has the right idea for part-timers; health law 'beyond rescue;' fighting back to secure the right to abortion

The big noise on the health insurance front today was sounded by Target, which announced via a corporate blog that it's ending health insurance for its part-time workers. Instead of signing up for a company plan, they're encouraged to use the health care exchanges set up through the Affordable Care Act. ...

24 Jan 2014

Single stem cell injection after meniscus knee surgery may provide pain relief, aid in meniscus regrowth

A single stem cell injection following meniscus knee surgery may provide pain relief and aid in meniscus regrowth, according to a novel study appearing in the January issue of the Journal of Bone and Joint Surgery (JBJS).

17 Jan 2014

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

The Finnish Degenerative Meniscal Lesion Study (FIDELITY) compared surgical treatment of degenerative meniscal tears to placebo surgery.

27 Dec 2013

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013

AudioEducator presents audio conferences on latest CPT coding updates for 2014

The providers want accurate reimbursement, whereas the payers want efficient claims processing. The ever-changing CPT® code set doesn't make your job easy. According to the American Medical Association (AMA), there will be 335 total code changes in 2014, to include 175 new codes, 107 revised codes, and 47 deleted codes.

12 Dec 2013

Mitek Sports Medicine adds RIGIDFIX Curve Cross Pin System to enable anatomic ACL reconstruction

Mitek Sports Medicine*, a leader in orthopaedics sports medicine and a part of the DePuy Synthes Companies of Johnson & Johnson, announced it has added the RIGIDFIX® Curve Cross Pin System, the first of its kind, designed specifically for use with the anteromedial (AM) portal approach to enable a more anatomic ACL (anterior cruciate ligament) reconstruction.

8 Nov 2013

NHMRC awards over $6M for Griffith University research projects

Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.

28 Oct 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

Omeros announces positive data from OMS824 Phase 1 clinical trial

Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.

12 Sep 2013

Omeros seeks EMA's approval to market OMS302 for patients undergoing ILR surgery

Omeros Corporation today announced that it recently submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market OMS302 for use in patients undergoing intraocular lens replacement surgery in the European Union.

10 Sep 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Omeros submits OMS302 NDA to FDA for patients undergoing ILR surgery

Omeros Corporation announced that the company recently submitted a New Drug Application to the U.S. Food and Drug Administration for approval of OMS302 for use in patients undergoing intraocular lens replacement surgery.

1 Aug 2013

NovoStitch suture passer now available for minimally invasive arthroscopic surgical procedures

Ceterix Orthopaedics, Inc. today announced commercial availability of the company's NovoStitch suture passer in the United States. The company's device enables surgeons to place stitches in tight joint compartments, including those in knees, hips and shoulders, during minimally invasive arthroscopic surgical procedures.

16 Jul 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.

13 Jun 2013

Use of child safety restraint systems decrease mortality rates during motor vehicle crashes

Supplemental child restraints should be used by all children through age 8. When appropriate child safety restraint systems-based on a child's age and weight-are in use during motor vehicle crashes, the rates of mortality and serious injury significantly decrease. Most parents don't know that their older children-ages 4 to 8-should use additional measures to protect them from serious injury or death in case of a crash.

7 Jun 2013

Omeros announces positive results from OMS824 Phase 1 clinical program

Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.

31 May 2013

FDA clears Omeros' OMS824 IND for treatment of Huntington's disease

Omeros Corporation today announced that its Investigational New Drug Application to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration.

23 May 2013